FDA Finds Statins Not Linked To ALS; When Can A False Alarm Be Turned Off?
FDA's determination that statins do not increase the incidence of amyotrophic lateral sclerosis suggests that agency will continue to rely on data from placebo controlled trials to address concerns raised in post-marketing reports
You may also be interested in...
Agency responds to preliminary trial results by lifting the safety alert linking the inhaled anticholinergic to risk of stroke.
Agency says there is no evidence of either proton-pump inhibitor leading to cardiovascular risk.
FDA's announcement of an ongoing safety investiation regarding a possible increased risk of cardiac events with AstraZeneca's Prilosec (omeprazole) and Nexium (esomeprazole) is the first test case of the agency's new policy of releasing emerging drug safety information